|Articles|June 1, 1998

Treatment of Heart Failure: A Managed Care Perspective
Volume 4
Issue 6 Suppl

Epidemiology, Prevalence, Treatments, and Clinical Trials

Author(s)Mihai Gheorghiade, MD

Download PDF: Epidemiology, Prevalence, Treatments, and Clinical Trials

Articles in this issue

about 28 years ago

Article

Participating Faculty

about 28 years ago

Article

Introduction: Treatment of Heart Failure: A Managed Care Perspective

about 28 years ago

Article

Clinical Practice Guidelines for Heart Failure

about 28 years ago

Article

Cost of Heart Failure to the Healthcare System

about 28 years ago

Article

Heart Failure and Disease Management

about 28 years ago

Article

Selected Abstracts

about 28 years ago

Article

CME Quiz

about 28 years ago

Article

Bibliography

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

Epidemiology, Prevalence, Treatments, and Clinical Trials

Articles in this issue

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Trending on AJMC

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year

GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis

Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes

Childhood Influenza Vaccine Rates Decreased From 2017 to 2023